The Evaluation of Interferon Lambda 4 rs368234815 Polymorphism in Patients with Chronic Hepatitis C.

Abstract

Background: Interferon lambda 4(FNL -4 rs368234815) predicts the HCV clearance and assess the predictive value of the IFNL4 polymorphism in the treatment of chronic HCV in Egyptian patients and its allele frequency in HCV patients compared with controls .Direct-acting antivirals (DAAs) has seen a significant increase of the patients with hepatitis C virus (HCV) clearing their infection. The INFL -4 rs368234815 was a powerful predictor of sustained virological response (SVR). Methods: Evaluation for IFNL4 rs368234815 polymorphism was performed by restriction fragment length polymorphism analysis (PCR- RFLP) in all participants. Results: Among 80 chronic HCV patients with IFNL4 rs368234815 Genotypes TT/TT, TT/GG, GG /GG, were present in 33.8%, 46.3%, and 20% of patients respectively, but among 20 persons that apparently healthy persons act as controls, the frequency was 80%, 15 %and 5% for TT/TT, TT/ GG, and GG /GG, respectively. IFNL4 GG genotype is correlated with poorer treatment reaction relative to TT genotype. The probability of spontaneous HCV clearance for IFNL4 rs368234815 TT/TT patients was higher than for the GG carriers. Determining IFNL4 SNPs before initiating treatment will be cost-effective and will reduce adverse effects. The INFL -4 rs368234815 was a powerful predictor of sustained virological response (SVR). Conclusions: In Hepatitis C virus patients, identifying the homozygosity in the variant GG of rs368234815 means a more potent prediction of HCV infection in HCV subjects that we observe in the variant homozygosity TT patients. InterferonL4 rs 368234815 polymorphism plays aprominant role in treatment and clearance of hepatitis C virus infection.